GDC-0941 Addict - Virtually All One Needs To Learn To Be Able To Master diglyceride

OS denotes survival free from death by any cause. The Kaplan-Meier method and log-rank test were used for survival analysis. Univariate and multivariate analyses were performed by using a backward Cox regression model with variables of p Selleckchem GDC941 univariate analysis. Mann-Whitney tests were used to compare means between the two groups. All values were two-sided, and statistical significance was accepted at a level of p of initial diagnosis ranged from February 2006 to March 2013, and the majority of patients had advanced diseases at the time of diagnosis. More than half of patients were in Ann Arbor stage IV (n=29, 67.4%), had two or more extranodal sites (n=23, 53.5%), and were diglyceride at high or high-intermediate risk (n=25, 58.1%) according to the standard IPI. A summary of patients�� characteristics is shown in Table 1. Table 1. Patient characteristics 2. Treatment and tumor response Prophylactic measures, doses and intervals of cytotoxic drugs, number of planned cycles, central nervous system (CNS) prophylaxis, and overall schedule of the regimen were as those in a previous study [11], except for administration of rituximab (two patients received 375 AZD0530 mw mg/m2 of rituximab on the first and eighth days of each cycle, whereas others received the same dose of rituximab on the first day of each cycle only). According to the recommendations of the Korean National Health Insurance Guideline, granulocyte-colony stimulating factor (G-CSF) was administered daily starting the first day patients showed an absolute neutrophil count (ANC) 3,000/��L in each cycle. Of the 32 evaluable patients, 24 patients (75%) achieved a CR, and six patients experienced disease progression in the final response evaluation (Table 2). Table 2. Results of interim and final response evaluations according to the revised criteria 3. Survival analysis Seven patients experienced relapse after CR, with two patients experiencing CNS involvement and five showing extra-CNS sites (two patients with skin and subcutaneous nodules, two patients with bone marrow involvement, and one patient with right inguinal lymph node involvement). After a median follow-up period of 20.0 months, the 2-year DFS, EFS, and OS rates of patients were 78.6%, 70.9%, and 81.4%, respectively (Fig. 1). According to univariate analysis, bone marrow involvement, an absolute lymphocyte count (ALC)